Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BCT006
MIFTS: 34

Bacterial Conjunctivitis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Bacterial Conjunctivitis

About this section

MalaCards integrated aliases for Bacterial Conjunctivitis:

Name: Bacterial Conjunctivitis 12 15 17 72
Conjunctivitis, Bacterial 44
Purulent Conjunctivitis 12

Classifications:

MalaCards categories:
Global: Infectious diseases Rare diseases
Anatomical: Eye diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9700
MeSH 44 D003234
NCIt 50 C53656
SNOMED-CT 68 17482009
ICD10 33 H10.0
UMLS 72 C0009768
Sources

Summaries for Bacterial Conjunctivitis

About this section
MalaCards based summary : Bacterial Conjunctivitis, also known as conjunctivitis, bacterial, is related to conjunctivitis and severe cutaneous adverse reaction. An important gene associated with Bacterial Conjunctivitis is TTC37 (Tetratricopeptide Repeat Domain 37), and among its related pathways/superpathways are Glycosphingolipid biosynthesis - lacto and neolacto series and terminal O-glycans residues modification. The drugs Moxifloxacin and Ethinyl Estradiol have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and testes.

Sources

Related Diseases for Bacterial Conjunctivitis

About this section

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis Rare Conjunctivitis

Diseases related to Bacterial Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 42)
# Related Disease Score Top Affiliating Genes
1 conjunctivitis 11.7
2 severe cutaneous adverse reaction 11.4
3 haemophilus influenzae 10.5
4 acute conjunctivitis 10.3
5 keratitis, hereditary 10.3
6 acute hemorrhagic conjunctivitis 10.1
7 chlamydia 10.1
8 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.0
9 eye disease 10.0
10 ophthalmia neonatorum 10.0
11 otitis media 9.9
12 bacterial infectious disease 9.9
13 corneal edema 9.9
14 inclusion conjunctivitis 9.9
15 blepharitis 9.9
16 48,xyyy 9.9
17 purpura fulminans 9.9
18 maxillary sinusitis 9.9
19 keratopathy 9.9
20 purpura 9.9
21 skin disease 9.9
22 measles 9.9
23 iridocyclitis 9.9
24 meningitis 9.9
25 anterior uveitis 9.9
26 neisseria meningitidis infection 9.9
27 pneumococcal meningitis 9.9
28 strabismus 9.8
29 streptococcus pneumonia 9.8
30 ophthalmomyiasis 9.8
31 myiasis 9.8
32 allergic conjunctivitis 9.8
33 trachoma 9.8
34 blepharoconjunctivitis 9.8
35 giant papillary conjunctivitis 9.8
36 papillary conjunctivitis 9.8
37 chronic conjunctivitis 9.8
38 endophthalmitis 9.8
39 eyelid disease 9.8
40 mechanical strabismus 9.8
41 pik3ca-related overgrowth syndrome 9.8
42 herpes simplex 9.8

Graphical network of the top 20 diseases related to Bacterial Conjunctivitis:



Diseases related to Bacterial Conjunctivitis
Sources

Symptoms & Phenotypes for Bacterial Conjunctivitis

About this section
Sources

Drugs & Therapeutics for Bacterial Conjunctivitis

About this section

DrugBank drugs 16 :

(show all 8)
# Drug Name Indication DrugBank ID
1 Azithromycin Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label]. Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. **Adults**: Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage. Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_. Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. **Pediatric Patients** Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy. DB00207
2 Besifloxacin Treatment of bacterial conjunctivitis. Bacterial isolates that are susceptible to besifloxacin include: CDC coryneform group G; Corynebacterium pseudodiphtheriticum; Corynebacterium striatum; Haemophilus influenzae; Moraxella lacunata; Staphylococcus aureus; Staphylococcus epidermidis; Staphylococcus hominis; Staphylococcus lugdunensis; Streptococcus mitis group; Streptococcus oralis; Streptococcus pneumoniae; Streptococcus salivarius* DB06771
3 Ciprofloxacin Ciprofloxacin is only indicated in infections caused by susceptible bacteria.[L6469,L6472,L6475,L6478,L6481,L6484,L6487,L6490,L6493] Ciprofloxacin immediate release tablets, oral suspensions, and intravenous injections are indicated for the treatment of skin and skin structure infections, bone and joint infections, complicated intra-abdominal infections, nosocomial pneumonia, febrile neutropenia, adults who have inhaled anthrax, plague, chronic bacterial prostatitis, lower respiratory tract infections including acute exacerbations of chronic bronchitis, urinary tract infections, complicated urinary tract infections in pediatrics, complicated pyelonephritis in pediatrics, and acute sinusitis.[L6481,L6478] A ciprofloxacin otic solution and otic suspension with hydrocortisone are indicated for acute otitis externa.[L6469,L6484] Ciprofloxacin suspension with dexamethasone is indicated for acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa.[L6490] A ciprofloxacin intratympanic injection is indicated for pediatric patients with bilateral otitis media with effusion who are having tympanostomy tubes placed or pediatric patients 6 months or older with acute otitis externa.[L6493] A ciprofloxacin eye drop is indicated for bacterial corneal ulcers and conjunctivitis.[L6472] A ciprofloxacin eye ointment is indicated for bacterial conjunctivitis.[L6475] A ciprofloxacin extended release tablet is indicated for uncomplicated urinary tract infections, complicated urinary tract infections, and acute uncomplicated pyelonephritis.[L6487] DB00537
4 Fusidic acid For the treatment of bacterial infections. DB02703
5 Gatifloxacin For the treatment of bronchitis, sinusitis, community-acquired pneumonia, and skin infections (abscesses, wounds) caused by S. pneumoniae, H. influenzae, S. aureus, M. pneumoniae, C. pneumoniae, L. pneumophila, S. pyogenes DB01044
6 Gentamicin For treatment of serious infections caused by susceptible strains of the following microorganisms: <i>P. aeruginosa</i>, <i>Proteus</i> species (indole-positive and indole-negative), <i>E. coli</i>, <i>Klebsiella-Enterobactor-Serratia</i> species, <i>Citrobacter</i> species and <i>Staphylococcus</i> species (coagulase-positive and coagulase-negative). DB00798
7 Levofloxacin For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: <i>Corynebacterium</i> species, <i>Staphylococus aureus</i>, <i>Staphylococcus epidermidis</i>, <i>Streptococcus pneumoniae</i>, <i>Streptococcus</i> (Groups C/F/G), Viridans group streptococci, <i>Acinetobacter lwoffii</i>, <i>Haemophilus influenzae</i>, <i>Serratia marcescens</i>. DB01137
8 Moxifloxacin For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye). DB00218

Drugs for Bacterial Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
2
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
3
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
4
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
5
Polyestradiol phosphate Approved Phase 4 28014-46-2
6 Contraceptives, Oral Phase 4
7 Contraceptives, Oral, Combined Phase 4
8 Contraceptive Agents Phase 4
9 Norgestimate, ethinyl estradiol drug combination Phase 4
10 Estradiol 3-benzoate Phase 4
11 Estradiol 17 beta-cypionate Phase 4
12
Neomycin Approved, Vet_approved Phase 3 1404-04-2 8378
13
Zinc Approved, Investigational Phase 3 7440-66-6 32051
14
Polymyxin B Approved, Vet_approved Phase 3 1404-26-8
15
Bacitracin Approved, Vet_approved Phase 3 1405-87-4 439542 10909430
16
Tobramycin Approved, Investigational Phase 3 32986-56-4 36294 5496
17
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
18
Sodium citrate Approved, Investigational Phase 3 68-04-2
19
Pentetic acid Approved Phase 3 67-43-6
20
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
21
Calcium polycarbophil Approved Phase 3 126040-58-2
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
24
Povidone Approved Phase 3 9003-39-8
25
Iodine Approved, Investigational Phase 3 7553-56-2 807
26
Povidone-iodine Approved Phase 3 25655-41-8
27
Vancomycin Approved Phase 3 1404-90-6 441141 14969
28
Besifloxacin Approved Phase 3 141388-76-3
29
Gatifloxacin Approved, Investigational Phase 3 112811-59-3 5379
30
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
31 Pazufloxacin Investigational Phase 3 127045-41-4
32 Tobramycin, Dexamethasone Drug Combination Phase 3
33 Dexamethasone, neomycin, polymyxin B drug combination Phase 3
34 Polymyxins Phase 3
35 Bacitracin zinc, neomycin sulfate, polymyxin B, drug combination Phase 3
36 Psyllium Phase 3
37 Citrate Phase 3
38 Anti-Infective Agents, Local Phase 3
39 Benzalkonium Compounds Phase 3
40 Gastrointestinal Agents Phase 3
41 Micronutrients Phase 3
42 Anti-Inflammatory Agents Phase 3
43 Antiemetics Phase 3
44 HIV Protease Inhibitors Phase 3
45 glucocorticoids Phase 3
46
protease inhibitors Phase 3
47 Hormones Phase 3
48 Antineoplastic Agents, Hormonal Phase 3
49 Nutrients Phase 3
50 Trace Elements Phase 3

Interventional clinical trials:

(show all 39)
# Name Status NCT ID Phase Drugs
1 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
2 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
3 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
4 RANDOMIZED CLINICAL EVALUATION OF EFFECTIVENESS COMPARISON BETWEEN DRUGS OPHTHALMOLOGICAL TOBRACORT® (TOBRAMYCIN + DEXAMETHASONE - LAB. UNIÃO QUÍMICA)AND TOBRADEX® (TOBRAMYCIN + DEXAMETHASONE - LAB. ALCON) IN REDUCING THE SIGNS AND SYMPTOMS OF ACUTE BACTERIAL CONJUNCTIVITIS Unknown status NCT01227915 Phase 3 Tobracort;Tobradex
5 Randomized Clinical Trial Of Drug Topics Efficacy Maxinom® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Union Chemical) And Maxitrol® (Dexamethasone + Neomycin Sulfate + Polymyxin B Sulfate - Lab. Alcon) In Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis Unknown status NCT01227863 Phase 3 MAXINOM®;Maxitrol®
6 An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients Completed NCT01573910 Phase 3 Moxifloxacin ophthalmic solution, 0.5%;Ofloxacin ophthalmic solution, 0.3%
7 AL-15469A for the Treatment of Bacterial Conjunctivitis Completed NCT00331916 Phase 3 quinolone
8 Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis Completed NCT00759148 Phase 3 Moxifloxacin Alternative Formulation (AF) Ophthalmic Solution 0.5%
9 A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vigamox in the Treatment of Bacterial Conjunctivitis Completed NCT00348348 Phase 3 Besifloxacin;Moxifloxacin solution
10 A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis. Completed NCT00347932 Phase 3 ISV-403;Vehicle
11 A Single- Centre, Randomised Study Of The Clinical And Microbiological Efficacy Of Decreasing The Dosage Of Levofloxacin 0,5% Eye Drops As Compared To Standard Eye Drop Dosage In Patients With Bacterial Conjunctivitis Completed NCT00565123 Phase 2, Phase 3 0.5% levofloxacin eye drops;0.5% levofloxacin eye drops
12 Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children. Completed NCT01155999 Phase 3 T1225;Tobramycin
13 A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis. Completed NCT00972777 Phase 2, Phase 3 Besifloxacin;Vehicle (Placebo)
14 An Evaluation of the Safety and Efficacy of Moxifloxacin AF Ophthalmic Solution 0.5% for the Treatment of Bacterial Conjunctivitis in India Completed NCT00332293 Phase 3 Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%;Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
15 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00518089 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
16 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis Completed NCT00509873 Phase 3 Gatifloxacin 0.5% eye drops;placebo eye drops
17 Clinical Efficacy and Safety of T1225 1.5% Eye Drops (3-Day Treatment) Versus Tobramycin 0.3 % Eye Drops (7-Day Treatment) in the Treatment of Purulent Bacterial Conjunctivitis Completed NCT00357773 Phase 3 Azithromycin (T1225)
18 A Study to Evaluate the Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle Following Three Times Daily(TID) Dosing for 7 Days Completed NCT01175590 Phase 3 Besivance;Vehicle
19 A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0 % AzaSite Compared to Vehicle in the Treatment of Bacterial Conjunctivitis Completed NCT00105534 Phase 3 AzaSite
20 A Study to Evaluate the Clinical and Microbial Efficacy and Safety of 1.0% AzaSite Compared to 0.3% Tobramycin Ophthalmic Solution in the Treatment of Bacterial Conjunctivitis Completed NCT00105469 Phase 3 AzaSite;Tobramycin
21 A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis Completed NCT03004924 Phase 3 SHP640;PVP-I 0.6%;Placebo
22 A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis Completed NCT02432807 Phase 3 Vancomycin 1.1%;Placebo
23 Clinical Study of the Efficacy of the Ophthalmic Solution of Pazufloxacin 0.6% (PRO-157) for the Treatment of Acute Bacterial Conjunctivitis, Compared to the Ophthalmic Solution of Gatifloxacin 0.3%. Recruiting NCT03696342 Phase 3 Pazufloxacin;Zymar
24 Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis and Death: a Phase III Double-blind Randomized Clinical Trial Recruiting NCT03199547 Phase 3 Azithromycin;Placebo Oral Tablet
25 A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis Terminated NCT01740388 Phase 3 Besifloxacin;Vehicle
26 Evaluation of the Safety and Efficacy of Topical Besifloxacin Ophthalmic Suspension, 0.6% Compared With Gatifloxacin, 0.3% Ophthalmic Solution for the Treatment of Presumed Bacterial Conjunctivitis in Subjects From Birth to 31 Days of Age Terminated NCT01330355 Phase 3 Besivance;Gatifloxacin
27 Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection Withdrawn NCT01721694 Phase 3 azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
28 A Study to Evaluate the Clinical and Microbial Efficacy of 0.6% ISV-403 Compared to Vehicle in the Treatment of Bacterial Conjunctivitis Completed NCT00622908 Phase 2 ISV-403;Vehicle
29 A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis Completed NCT01877694 Phase 2 Auriclosene Solution 0.3%;Auriclosene Vehicle
30 A Randomized, Double Blind, Phase II Multicenter Trial to Evaluate the Safety and Efficacy of PRO-157 Ophthalmic Solution in Three Different Dosing Regimen Versus Moxifloxacin Versus Gatifloxacin in Patients With Bacterial Conjunctivitis. Completed NCT02980523 Phase 2 PRO-157;Vigamox;Zymar®;Lagricel Ofteno®
31 A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers Completed NCT00386958 Phase 2 Povidone-Iodine
32 Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis Withdrawn NCT01238783 Phase 2 AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension;AL-15469A 0.5%;AL-6515 0.3%;Vehicle
33 Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers Unknown status NCT03235141 Phase 1 azithromycin eye drops by essex;azithromycin eye drops
34 Systemic Pharmacokinetics of BOL-303224-A After Single and Multiple Instillations of BOL-303224-A in Subjects With Suspected Bacterial Conjunctivitis Completed NCT00407589 Phase 1 BOL-303224-A
35 Phase I Clinical Trial, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-174 Versus Sophixín Ofteno®, Elaborated by Laboratorios Sophia on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects Recruiting NCT03519516 Phase 1 PRO-174;Sophixín Ofteno®
36 Study to Evaluate the Safety and Tolerability of Pro-143 Ophthalmic Solution in Healthy Volunteers. Withdrawn NCT03698045 Phase 1 PRO-143 Ophthalmic Solution
37 Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study Unknown status NCT02497365 Besifloxacin;Tobramycin and Cefazolin
38 Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists Recruiting NCT03987178
39 Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF Recruiting NCT03255369

Search NIH Clinical Center for Bacterial Conjunctivitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Azithromycin
Besifloxacin
Ciprofloxacin
Ciprofloxacin
Fusidic acid
Gatifloxacin
Gentamicin
Levofloxacin
Loteprednol
loteprednol etabonate
Moxifloxacin

Cochrane evidence based reviews: conjunctivitis, bacterial

Sources

Genetic Tests for Bacterial Conjunctivitis

About this section
Sources

Anatomical Context for Bacterial Conjunctivitis

About this section

MalaCards organs/tissues related to Bacterial Conjunctivitis:

41
Eye, Skin, Testes, Colon, Kidney, Neutrophil
Sources

Publications for Bacterial Conjunctivitis

About this section

Articles related to Bacterial Conjunctivitis:

(show top 50) (show all 526)
# Title Authors PMID Year
1
Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation. 38
31372767 2019
2
Draft Whole-Genome Sequences of Haemophilus influenzae Biogroup aegyptius Strains Isolated from Five Brazilian Purpuric Fever Cases and One Conjunctivitis Case. 38
31346025 2019
3
Pharmacist Compliance With Therapeutic Guidelines on Diagnosis and Treatment Provision. 38
31314116 2019
4
Chloramphenicol/sulfobutyl ether-β-cyclodextrin complexes in an ophthalmic delivery system: prolonged residence time and enhanced bioavailability in the conjunctival sac. 38
31033370 2019
5
Preparation and Evaluation of N-Trimethyl Chitosan Nanoparticles of Flurbiprofen for Ocular Delivery. 38
30632402 2019
6
Evaluation of a new patient consultation initiative in community pharmacy for ear, nose and throat and eye conditions. 38
31053122 2019
7
Acute allergic reaction caused by topical azithromycin eye drops: A report of two cases. 38
31384165 2019
8
Two Soft Contact Lenses Retained in the Superior Fornix for 15 Years in a Patient With Unique Orbital Anatomy. 38
30985489 2019
9
Topical Antibiotics for Clinical and Microbiologic Cure of Bacterial Conjunctivitis. 38
30421517 2019
10
Comment on article: “Zika, afebrile disease?” 38
30889338 2019
11
Chronic Conjunctivitis From a Retained Contact Lens. 38
30724838 2019
12
[Rehabilitation of Anophthalmic Patients with Prosthetic Eyes in Germany Today - Supply Possibilities, Daily Use, Complications and Psychological Aspects]. 38
30567009 2019
13
The efficacy and safety of besifloxacin for acute bacterial conjunctivitis: a Meta-analysis. 38
31236364 2019
14
Gonococcal Conjunctivitis in Adults: Case Report and Retrospective Review of Cases in Alberta, Canada, 2000-2016. 38
30044333 2019
15
Optimizing Accessibility of a Hand-wash Gel to Infant's Cradle: Effect on Neonatal Conjunctivitis. 38
29570175 2019
16
Correction to: Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial, by Baiza-Durán, L., Olvera-Montaño, O., Mercado-Sesma, A.R., and Oregon-Miranda, A.A. J Ocul Pharmacol Ther 2018;34(3):250-255. DOI: 10.1089/jop.2017.0056. 38
30699060 2019
17
A case report on complete cure of recurrent primary canaliculitis by 4-snip punctoplasty and canalicular curettage. 38
30544448 2018
18
[Right treatment of red eyes - prescription of topical antibiotics for infectious conjunctivitis is still common in Sweden]. 38
30561753 2018
19
Evaluation of content and cost of traditional eye medication in a resource-poor country - Implications for eye care practice and policy. 38
30417853 2018
20
Contact lenses with dual drug delivery for the treatment of bacterial conjunctivitis. 38
29960036 2018
21
Management of Bacterial Conjunctivitis in Children-Preferred Practice Pattern in Northern Greece. 38
30157160 2018
22
Preparation and evaluation of novel chitosan: gelrite ocular system containing besifloxacin for topical treatment of bacterial conjunctivitis: scintigraphy, ocular irritation and retention assessment. 38
28708424 2018
23
Atypical presentation of cat scratch disease: Parinaud's oculoglandular syndrome with facial nerve paresis. 38
29982178 2018
24
Analysis of the drug therapy of gatifloxacin and levofloxacin in the treatment of acute bacterial conjunctivitis. 38
30203775 2018
25
Kawasaki Disease in the neonate: case report and literature review. 38
29970110 2018
26
Aetiology of neonatal conjunctivitis evaluated in a population-based setting. 38
29345007 2018
27
Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis. 38
29847658 2018
28
Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial. 38
29624493 2018
29
Seasonal distribution of ocular conditions treated at the emergency room: a 1-year prospective study. 38
29846426 2018
30
Improvement in Ocular Bioavailability and Prolonged Delivery of Tobramycin Sulfate Following Topical Ophthalmic Administration of Drug-Loaded Mucoadhesive Microparticles Incorporated in Thermosensitive In Situ Gel. 38
29211593 2018
31
Resistant Infantile Bacterial Conjunctivitis in Egypt: A Microbiology Study. 38
29131910 2018
32
Besifloxacin: A Critical Review of Its Characteristics, Properties, and Analytical Methods. 38
29345957 2018
33
Morganella as a cause of ophthalmia neonatorum. 38
29288840 2018
34
Patient demographic and microbiology trends in bacterial conjunctivitis in children. 38
29247795 2018
35
Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study. 38
30335799 2018
36
Gonococcal conjunctivitis: A case report. 38
30800230 2018
37
Sequelae from Epidemic Viral Conjunctivitis Can Be Associated with Inflammatory Trachoma in Schoolchildren? 38
27628039 2018
38
Bacterial Conjunctivitis in Childhood: Etiology, Clinical Manifestations, Diagnosis, and Management. 38
29380707 2018
39
Acute kidney injury and cholestasis associated with Kawasaki disease in a 9-year-old: Case report. 38
29254742 2017
40
Does azithromycin given to women in labour decrease ocular bacterial infection in neonates? A double-blind, randomized trial. 38
29282015 2017
41
Enhancement of lomefloxacin Hcl ocular efficacy via niosomal encapsulation: in vitro characterization and in vivo evaluation. 38
27241274 2017
42
Clinical, laboratory and virological data from suspected ZIKV patients in an endemic arbovirus area. 38
28918127 2017
43
A chronological study of the bacterial pathogen changes in acute neonatal bacterial conjunctivitis in southern China. 38
28950852 2017
44
[Neisseria gonorrhoeae: an infrequent causal agent of periorbital cellulitis in a child]. 38
28737877 2017
45
Prevalence of ocular morbidity in school going children in West Uttar Pradesh. 38
28643716 2017
46
Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin HCl. 38
27079800 2017
47
Zika Virus Infection in Pregnant Women and Microcephaly. 38
28575919 2017
48
Neonatal Bacterial Conjunctivitis in Korea in the 21st Century. 38
28002109 2017
49
Epidemiology of bacterial conjunctivitis in chinchillas (Chinchilla lanigera): 49 cases (2005 to 2015). 38
28276116 2017
50
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates. 38
28078599 2017
Sources

Variations for Bacterial Conjunctivitis

About this section
Sources

Expression for Bacterial Conjunctivitis

About this section
Search GEO for disease gene expression data for Bacterial Conjunctivitis.
Sources

Pathways for Bacterial Conjunctivitis

About this section

Pathways related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Glycosphingolipid biosynthesis - lacto and neolacto series 37
10.39 ST3GAL3 GCNT2
2
terminal O-glycans residues modification 1
9.53 ST3GAL3 GCNT2
Sources

GO Terms for Bacterial Conjunctivitis

About this section

Biological processes related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein glycosylation GO:0006486 8.62 ST3GAL3 GCNT2

Molecular functions related to Bacterial Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity, transferring glycosyl groups GO:0016757 8.62 ST3GAL3 GCNT2
Sources

Sources for Bacterial Conjunctivitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....